IMRT 2018

SABR in stage I histologically proven NSCLC: an Italian multicenter observational study

OVERALL SURVIVAL

2B

1,0

DOM FROM LOCAL RECURRENCE REEDOM FROM NODAL RECURR NCE

FREEDOM FROM NODAL RECURRENCE

6.7 ear: 91.9

% 2 years: 90.9

% 3 years: 89.7

% 1 year: 91.9

% 2 years: 89.0

% 3 years: 85.5

% 2 years: 89.0

% 3 years: 85.5

0,8

0,6

DOM FROM DISTANT RECURRENCE DISEASE FREE SURVIVAL

DISEASE FREE SURVIVAL

0.4 ear: 82.9

% 2 years: 80.4

% 3 years: 75.9

% 1 year: 82.9

% 2 years: 70.2

% 3 years: 65.5

% 2 years: 70.2

% 3 years: 65.5

0,4

CANCER SPECIFIC SURVIVAL OVERALL SURVIVAL

OVERALL SURVIVAL

0,2

7.2

% 2 years: 88.9

% 3 years: 82.1

% 1 year: 94.0

% 2 years: 81.6

% 3 years: 68.0

ear: 94.0

% 2 years: 81.6

% 3 years: 68.0

0,0

96,00

,00

12,00

24,00

36,00

48,00

60,00

72,00

84,00

96,00

Time since enrollement (months)

Number at risk

196 165 107 63 37 15 7 4 1

1

Ricardi et al, Lung Cancer 2014